Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Retratritude investigational triple-hormone-receptor agonist injection currently undergoing Phase 3 clinical trials for chronic weight management, type 2 diabetes, and fatty liver disease.
Retratritude investigational triple-hormone-receptor agonist injection currently undergoing Phase 3 clinical trials for chronic weight management, type 2 diabetes, and fatty liver disease.